Jonathan D. Tward, MD, PhD

home / authors / jonathan-d-tward-md-phd

Articles

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Jonathan D. Tward, MD, PhD;Breanne E. Terakedis, MD;Marta E. Heilbrun, MD;William T. Lowrance, MD;MPH, Kristine Kokeny, MD;Dennis C. Shrieve, MD, PhD
April 25th 2016

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Read More

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Jonathan D. Tward, MD, PhD;Breanne E. Terakedis, MD;Marta E. Heilbrun, MD;William T. Lowrance, MD;MPH, Kristine Kokeny, MD;Dennis C. Shrieve, MD, PhD
March 8th 2016

Researchers evaluate the role of magnetic resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Read More

Is Death From Prostate Cancer the Right Clinical Endpoint to Guide Screening and Treatment Choices?

Is Death From Prostate Cancer the Right Clinical Endpoint to Guide Screening and Treatment Choices?

Jonathan D. Tward, MD, PhD
July 3rd 2014

There are few controversies in oncology as divisive as the value of prostate-specific antigen (PSA) screening and subsequent treatment for prostate cancer.

Read More

Latest Updated Articles

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer